Cetera Investment Advisers increased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:

Initiation of study marks an important milestone in advancing Neurocrine's obesity portfolio and

Initiation of study marks an important milestone in advancing Neurocrine's obesity portfolio and inv

Canaccord Genuity analyst Sumant Kulkarni maintains Neurocrine Biosciences (NASDAQ:NBIX) with a B

Truist Securities analyst Danielle Brill maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Bu

Wedbush analyst Laura Chico maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and

Glenmede Trust Co. NA reduced its holdings in Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 3.8% in

Citigroup analyst Yigal Nochomovitz maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and

RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperfo

Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-W

TD Cowen analyst Phil Nadeau maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises

Neurocrine expands its portfolio with INGREZZA, CRENESSITY and VYKAT XR growth, while advancing pipe

Piper Sandler analyst David Amsellem maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overwe

Cantor Fitzgerald analyst Josh Schimmer maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Ove

Guggenheim analyst Yatin Suneja maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and rai

Stifel analyst Paul Matteis maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises

Needham analyst Ami Fadia maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises th

Neurocrine Biosciences, Inc. (NBIX) Q2 2026 Earnings Call Transcript

The headline numbers for Neurocrine (NBIX) give insight into how the company performed in the quarte

Neurocrine Biosciences (NBIX) came out with quarterly earnings of $2.85 per share, beating the Zacks

Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings of $2.85 per share which beat the a

Total Second-Quarter 2026 Revenue Grew 39% Year-Over-Year to $959 Million INGREZZA ® (valbenazine) 2

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Neurocrine (NBIX), delve int

NBIX heads into Q2 results with a focus on Ingrezza sales, Crenessity growth and pipeline updates as

SAN DIEGO, July 23, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced

Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings b

California Public Employees Retirement System raised its position in shares of Neurocrine Bioscience

SAN DIEGO, July 21, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced

Guggenheim analyst Brad Canino maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and rais

Wells Fargo analyst Mohit Bansal maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight

NVIDIA, Neurocrine and Ball screen well for earnings growth and rising estimates, highlighting stock

Neurocrine Biosciences (NBIX) shares have started gaining and might continue moving higher in the ne

Truist Securities analyst Danielle Brill maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Bu

BMO Capital analyst Evan Seigerman maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Market P

Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the mark

Biopharmaceutical firm Neurocrine Biosciences, Inc. (NBIX) up over 35% in a year and 17% since outli

Conference Call and Webcast Scheduled for Thursday, July 30 SAN DIEGO, July 9, 2026 /PRNewswire/ --

Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this we

Tom Lee's GRNJ added First Solar, Zoom and eight other stocks in its latest rebalance as assets

Neurocrine (NBIX) to acquire Soleno Therapeutics (SLNO) for $2.9B to expand its rare disease portfol

Neurocrine's Phase 2 trial of NBI-1070770 in major depressive disorder missed its main goal but

A powerful surge in AI-related stocks — led by a 9% advance in NVIDIA Corp. (NASDAQ:NVDA) over the p

Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session.